These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38071439)

  • 1. Ceftazidime-avibactam use for the treatment of OXA-48- and/or New Delhi metallo-β-lactamase-producing
    Alghamdi A; AlQahtani H; Albilal S; Mater Almutairi M; Alobaidallah N; Alghamdi L; Alfayez A; Almangour T; Al-Jedai A
    Ann Saudi Med; 2023; 43(6):373-379. PubMed ID: 38071439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Features and Outcomes of Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area.
    Falcone M; Giordano C; Leonildi A; Galfo V; Lepore A; Suardi LR; Riccardi N; Barnini S; Tiseo G
    Clin Infect Dis; 2024 May; 78(5):1111-1119. PubMed ID: 38036465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ceftazidime/avibactam for treatment of carbapenemase-producing carbapenem-resistant Enterobacterales with OXA-48 and/or NDM genes with or without combination therapy.
    Alqahtani H; Alghamdi A; Alobaidallah N; Alfayez A; Almousa R; Albagli R; Shamas N; Farahat F; Mahmoud E; Bosaeed M; Abanamy R
    JAC Antimicrob Resist; 2022 Oct; 4(5):dlac104. PubMed ID: 36237571
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Stone G; Wise M; Utt E
    Microbiol Spectr; 2024 Mar; 12(3):e0147323. PubMed ID: 38329363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.
    Larcher R; Laffont-Lozes P; Roger C; Doncesco R; Groul-Viaud C; Martin A; Loubet P; Lavigne JP; Pantel A; Sotto A
    Front Cell Infect Microbiol; 2022; 12():1048633. PubMed ID: 36544909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection.
    Rawson TM; Brzeska-Trafny I; Maxfield R; Almeida M; Gilchrist M; Gonzalo X; Moore LS; Donaldson H; Davies F
    J Glob Antimicrob Resist; 2022 Jun; 29():558-562. PubMed ID: 35131508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing
    Isler B; Ezure Y; Romero JLG; Harris P; Stewart AG; Paterson DL
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.
    Kalaivani R; Kali A; Surendran R; Sujaritha T; Ganesh Babu CP
    Indian J Med Microbiol; 2024; 47():100530. PubMed ID: 38246242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
    Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
    mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
    De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA
    Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales.
    Ozyurt OK; Tufanoglu P; Cetinkaya O; Ozhak B; Yazisiz H; Ongut G; Turhan O; Ogunc D
    Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
    Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F
    Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales.
    Khan S; Das A; Vashisth D; Mishra A; Vidyarthi AJ; Gupta R; Begam NN; Kataria B; Bhatnagar S
    PLoS One; 2024; 19(5):e0303753. PubMed ID: 38758757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India.
    Sree RA; Gupta A; Gupta N; Veturi S; Reddy LSK; Begum M; Shravani E; Challa HR; Reddy SS; Singamsetty A; Arumilli M; Reddy PN; Tirlangi PK
    Infection; 2024 Apr; 52(2):429-437. PubMed ID: 37697224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales.
    Satlin MJ; Chen L; Gomez-Simmonds A; Marino J; Weston G; Bhowmick T; Seo SK; Sperber SJ; Kim AC; Eilertson B; Derti S; Jenkins SG; Levi MH; Weinstein MP; Tang YW; Hong T; Juretschko S; Hoffman KL; Walsh TJ; Westblade LF; Uhlemann AC; Kreiswirth BN
    Clin Infect Dis; 2022 Dec; 75(12):2066-2075. PubMed ID: 35522019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales.
    Mataraci Kara E; Yilmaz M; Istanbullu Tosun A; Özbek Çelik B
    J Chemother; 2020 Jul; 32(4):171-178. PubMed ID: 32375606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
    Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
    Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
    Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.